Empirical Asset Management LLC Takes $606,000 Position in Medpace Holdings, Inc. $MEDP

Empirical Asset Management LLC bought a new position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) during the 2nd quarter, Holdings Channel reports. The institutional investor bought 1,145 shares of the company’s stock, valued at approximately $606,000.

Other large investors have also recently bought and sold shares of the company. BlackRock Inc. acquired a new position in shares of Medpace during the 2nd quarter worth approximately $1,323,047,000. AQR Capital Management LLC grew its stake in shares of Medpace by 31.6% in the fourth quarter. AQR Capital Management LLC now owns 1,349,703 shares of the company’s stock valued at $758,061,000 after buying an additional 324,293 shares in the last quarter. Wasatch Advisors LP increased its holdings in Medpace by 14.0% during the second quarter. Wasatch Advisors LP now owns 945,814 shares of the company’s stock worth $296,853,000 after buying an additional 116,354 shares during the last quarter. Geode Capital Management LLC raised its position in Medpace by 3.8% during the fourth quarter. Geode Capital Management LLC now owns 667,298 shares of the company’s stock worth $374,836,000 after acquiring an additional 24,625 shares in the last quarter. Finally, Invesco Ltd. raised its position in Medpace by 18.9% during the third quarter. Invesco Ltd. now owns 537,407 shares of the company’s stock worth $276,313,000 after acquiring an additional 85,517 shares in the last quarter. 77.98% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Medpace

In related news, VP Susan E. Burwig sold 7,500 shares of the business’s stock in a transaction on Tuesday, July 28th. The stock was sold at an average price of $600.00, for a total value of $4,500,000.00. Following the completion of the sale, the vice president directly owned 62,984 shares in the company, valued at $37,790,400. The trade was a 10.64% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO August J. Troendle sold 17,610 shares of the business’s stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $605.11, for a total value of $10,655,987.10. Following the completion of the sale, the chief executive officer owned 615,802 shares of the company’s stock, valued at $372,627,948.22. This trade represents a 2.78% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 67,195 shares of company stock worth $37,989,998 over the last three months. Company insiders own 20.50% of the company’s stock.

Medpace Stock Performance

Shares of MEDP opened at $590.30 on Wednesday. Medpace Holdings, Inc. has a 52 week low of $373.00 and a 52 week high of $677.90. The firm has a market cap of $16.48 billion, a P/E ratio of 34.60, a price-to-earnings-growth ratio of 2.58 and a beta of 1.15. The firm’s 50-day simple moving average is $541.49 and its 200 day simple moving average is $491.49.

Medpace (NASDAQ:MEDP) last released its quarterly earnings results on Wednesday, July 22nd. The company reported $4.25 earnings per share for the quarter, beating the consensus estimate of $3.98 by $0.27. The firm had revenue of $707.33 million for the quarter, compared to analysts’ expectations of $689.51 million. Medpace had a net margin of 17.67% and a return on equity of 110.15%. The business’s revenue was up 17.2% on a year-over-year basis. During the same period in the prior year, the firm earned $3.10 EPS. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. As a group, equities analysts forecast that Medpace Holdings, Inc. will post 17.54 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on MEDP. Royal Bank Of Canada boosted their price objective on shares of Medpace from $484.00 to $692.00 and gave the stock an “outperform” rating in a research note on Friday, July 24th. TD Cowen raised their target price on shares of Medpace from $419.00 to $492.00 and gave the company a “hold” rating in a research note on Friday, July 24th. Jefferies Financial Group cut Medpace from a “buy” rating to a “hold” rating and lifted their price target for the stock from $490.00 to $515.00 in a report on Tuesday, July 7th. Mizuho boosted their price target on Medpace from $586.00 to $665.00 and gave the stock an “outperform” rating in a research report on Friday, July 24th. Finally, Deutsche Bank Aktiengesellschaft restated a “hold” rating and issued a $535.00 price objective on shares of Medpace in a research note on Thursday, July 23rd. Three research analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and an average price target of $584.18.

Medpace Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.